The synthesis of mitozolomide was reported by Stevens et al. (1984) and pre-clinical trials have indicated that it possesses cytotoxic activity against a number of animal tumours (Hickman et al., 1985) . Phase II clinical studies have shown moderate antitumour activity (Gunderson et al., 1987) , and an early phase clinical study with autologous bone marrow rescue is in progress at Wellington Hospital. In the Wellington Hospital study one patient underwent a course of radiotherapy following treatment with mitozolomide. The patient had a urethral carcinoma which did not respond to mitozolomide, but after radiotherapy the lesion regressed dramatically. This chance observation led us to consider the possibility that mitozolomide had acted as a radiation sensitiser.
It has been suggested that mitozolomide cytotoxicity is due to DNA interstrand cross-linkage, following alkylation of guanine bases (Gibson et al., 1984a, b) . In this respect mitozolomide appears similar to BCNU (1,3 bis (2-chloroethyl)-l-nitrosourea) and other nitrosoureas (Kohn, 1977) . Radiation can enhance interstrand cross-linking by BCNU (Tofilon et al., 1984) . Cross-linking agents have also been found to enhance radiation-induced cell killing in mammalian cells in vitro (Nias, 1985; Wheeler et al., 1977) and the combination can be more effective in vivo than the single agents (Barker et al., 1979; Walker & Gehan, 1976) .
We have therefore investigated the hypothesis that mitozolomide enhances radiation damage using mammalian cells in vitro. Chinese hamster ovary (AA8 sub-line) cells were maintained at 37°C as monolayer cultures in minimal essential medium (alpha-modification) with 10% fetal calf serum and without added antibiotics. Sub-culture was carried out bi-weekly. Once cells in late log phase had been trypsinised for use in experiments the fetal calf serum was reduced to 5% and penicillin (100pgml-1) and streptomycin (100 #g ml-1) added. This latter medium was also used to plate out and incubate the cells.
Mitozolomide was provided by Rhone Poulenc (NZ) Ltd and made up just prior to use by dissolving the powder in dimethylsulphoxide and subsequent dilution into growth medium. The maximum dimethylsulphoxide concentration in the cultures (0.7% v/v) had no effect on cell viability. Cells were exposed to the drug for 1 h, usually by careful addition of the drug to the monolayer cultures. However, in a few experiments the drug was added to cells in suspension. Drug toxicity was similar in monolayer and suspension culture.
After drug exposure the medium was removed and the cells rinsed with medium and either trypsinised immediately or re-incubated with fresh, drug-free medium for a given period before trypsinisation. The cells were centrifuged and resuspended at about 106 cells ml -I in the complete medium. After 20min re-equilibration at 37°C in an atmosphere of 5% CO2 95% air, the cells were irradiated in small stoppered glass vessels. The irradiation source (AECL, Gammacell 220) provided a gamma-ray dose rate of about 7Gymin-1. Figure 1 indicates that when irradiated 8 h later the cells surviving the drug treatment were more sensitive to radiation than non-treated controls (P< 0.005). Lower concentrations had a greatly reduced toxic effect. Mitozolomide at 10 umoldm-3 resulted in a surviving fraction of about 0.8 and 8h later did not produce any radiosensitisation of the cells which survived the drug treatment (P> 0.3).
The enhancing effect of the drug was measured by the ratio of doses required to achieve a given surviving fraction in control and drug-treated cells. This enhancement ratio (ER) is 1.25 + 0.04 throughout the survival range 0.2-0.001 for the curves in Figure 1 fitted by equation [1] . Thus mitozolomide pre-treatment appears to act as a simple dose modifying agent.
The importance of the scheduling of the drug and radiation treatments was also investigated (Figure 2) . Enhancement was observed when the radiation exposure followed drug treatment by 4-12h. Longer or shorter delays before irradiation resulted in almost no enhancement. The comparatively greater error bars at 4h in Figure 2 reflect the greater variation in the degree of enhancement found at this time. Separate experiments showed that allowing mitozolomide to remain in contact with the cells during the irradiation had no effect on the radiation response.
A number of explanations for our results are possible. In view of the need for toxic drug concentrations and the (0) Horgan et al. (1983) have reported briefly on a flow cytometric analysis of mitozolomide-treated cells. Mitozolomide under conditions described as minimally toxic depleted the G1 cell fraction and produced a block in the cell cycle at G2/M. Broggini et al. (1986) reported similar results with mitozolomide treatment of tumour-bearing mice (10mgkg-1). Cell cycle effects less than 24h after treatment were not examined, but appeared to peak about 48 h after treatment. Although the experimental conditions differed from ours, the flow cytometry results lend some support to an explanation of our results based on cell cycle effects. However, the results of Broggini et al. (1986) indicate that the time course of radiosensitisation may differ from cell cycle effects. Gibson et al. (1984a,b) noted that maximum DNA crosslinkage occurred some 12h after mitozolomide treatment of a transformed cell line. This is near the peak of the period in which radiation enhancement occurred. It is not possible at present to tell whether this is a coincidental finding or an indication that DNA cross-linking and radiation enhancement are directly related. However, a normal cell line, which was proficient in repair of the initial guanine adducts, demonstrated little cross-linking.
Another possible explanation is that mitozolomide interferes with the accumulation or repair of sub-lethal or potentially lethal damage. This was the explanation tentatively favoured for the enhancement brought about by BCNU in rat 9L brain tumour cells in vitro (Wheeler et al., 1977) . Since BCNU is thought to have similarities with mitozolomide in its cytotoxic mode of action (Gibson et al., 1984a; Horgan & Tisdale, 1984) , a similar explanation for mitozolomide should be considered. The maximum enhancement by BCNU at surviving fractions of 0.1 or less is similar to the enhancement by mitozolomide, and this maximum effect also occurred some 5-15h after BCNU treatment.
However, the differences between the two drugs are even more notable. BCNU provided enhancement at relatively non-toxic concentrations and with a far wider range of schedules than found with mitozolomide, including simultaneous treatments and irradiation before drug treatment. The principal effect of BCNU, seen with all schedules, was to reduce the shoulder on the radiation survival curve, whereas enhancement by mitozolomide was reasonably constant throughout the dose range.
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